Friday 16 October 2026
Export CUE’s income statement to Excel — free account
Cue Biopharma, Inc.
Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024. In the quarter to June 2026, revenue grew 166.7%, EPS fell 793.2% and free cash flow fell 742.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
16.96
1.71
−9.16%
Follow CUE
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 124.80 | 136.80 | 279.00 | 289.56 | 65.40 | 51.00 | 13.50 | 6.90 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | 539.70 | 539.70 | 950.70 | 552.60 | 382.20 | 153.60 | 96.00 | 52.50 | |||||
| People | |||||||||||||||
| People | Employees | 28 | 30 | 47 | 47 | 52 | 59 | 51 | 53 | 41 | 29 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.02 | 0.07 | 0.06 | 0.25 | 0.02 | 0.10 | 0.23 | 0.95 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 1 | 3 | 3 | 15 | 1 | 5 | 9 | 27 | ||||
| Gross margin, % | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | (8) | (23) | (38) | (36) | (45) | (44) | (53) | (51) | (41) | (26) | |||||
| EBT margin, % | 0.00 | 0.00 | (3,339.34) | (1,049.26) | (1,413.27) | (292.25) | (4,257.83) | (924.10) | (437.97) | (95.03) | |||||
| Net income | (8) | (23) | (39) | (37) | (45) | (44) | (53) | (51) | (41) | (27) | |||||
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 1.70 | 4.71 | 3.30 | 14.34 | 1.05 | 3.60 | 4.95 | 8.71 | ||||
| Earnings | (30.94) | (65.01) | (58.26) | (49.85) | (46.85) | (42.34) | (44.74) | (33.33) | (21.62) | (8.41) | |||||
| Cash flow | (24.11) | (33.97) | (39.39) | (41.96) | (34.01) | (37.28) | (35.22) | (26.23) | (19.37) | (6.87) | |||||
| Capex | (2.08) | (3.37) | (2.77) | 0.11 | (0.62) | (0.86) | (0.14) | 0.00 | 0.02 | (0.04) | |||||
| Free cash flow | (26.20) | (37.34) | (42.16) | (41.85) | (34.64) | (38.13) | (35.36) | (26.23) | (19.35) | (6.92) | |||||
| Book value | 61.31 | 172.38 | 50.67 | 74.37 | 82.60 | 62.86 | 55.33 | 24.34 | 9.33 | 8.38 | |||||
| Shares, m | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 0.00 | 101.08 | 113.66 | 23.66 | 76.09 | 23.15 | 6.60 | 1.05 | |||||
| P/B | — | — | 2.78 | 6.40 | 4.54 | 5.40 | 1.44 | 3.43 | 3.51 | 1.09 | |||||
| EV/Sales | — | — | 0.00 | 85.58 | 89.02 | 20.02 | 22.84 | 15.74 | 4.70 | 0.08 | |||||
| EV/FCF | — | — | (1.96) | (9.64) | (8.48) | (7.53) | (0.68) | (2.16) | (1.20) | (0.10) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (6) | (12) | (26) | (31) | (32) | (39) | (42) | (40) | (36) | (22) | ||||
| Capex | (1) | (1) | (2) | 0 | (1) | (1) | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (6) | (13) | (28) | (31) | (33) | (40) | (42) | (40) | (36) | (22) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 14 | 60 | 34 | 49 | 71 | 56 | 66 | 34 | 11 | 23 | ||||
| Total debt | — | — | — | 6 | 7 | 10 | 10 | 8 | 4 | — | |||||
| Net debt | (15) | (64) | (39) | (54) | (78) | (54) | (66) | (41) | (19) | (28) | |||||
| Shareholders’ equity | 15 | 62 | 34 | 55 | 79 | 65 | 66 | 37 | 17 | 26 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (64.92) | (55.83) | (69.41) | (62.75) | (52.34) | (48.28) | (60.69) | (66.40) | (86.80) | (71.51) | ||||
| ROIC | (2,408.88) | 0.00 | 0.00 | (2,369.89) | (2,367.67) | (244.49) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (69.27) | (60.52) | (81.57) | (82.88) | (67.10) | (61.16) | (80.82) | (98.73) | (149.03) | (121.11) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Cue Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CDXS Codexis, Inc. | $148.9M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| MSLE Satellos Bioscience Inc. | $145.1M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TARA Protara Therapeutics, Inc. | $141.8M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $138.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NKTX Nkarta, Inc. | $138.2M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AVXL Anavex Life Sciences Corp. | $137.2M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | Compare |
| ANTX AN2 Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CUE Cue Biopharma, Inc. | $135.6M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | |
| Median of peers | $140.1M | — | — | −98.86% | — | +15.84% | 0.00% | 0.00% |
Cue Biopharma, Inc. (CUE) key facts
- Strength: Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024.
- Cue Biopharma, Inc. (CUE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CUE traded at $17.48, a market capitalization of $135.6 million.
- Return on equity was −121.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −11.88 (distress zone) for fiscal 2025.
Cue Biopharma, Inc. (CUE) Latest News
No news at this impact. Lower the threshold for more.